08:00 , Dec 19, 2013 |  BC Innovations  |  Translation in Brief

Translational tidbits

Consorting with academia GlaxoSmithKline plc has set up an immuno-oncology consortium that invites academics from six cancer centers to view its nonpublic early pipeline programs and share ideas for new therapeutic candidates. The Oncology Clinical...
08:00 , Dec 9, 2013 |  BC Week In Review  |  Company News

Prosensa B.V., Consultants for Research in Imaging and Spectroscopy (CRIS), Scito, Institute of Myology, Katholieke Universiteit Leuven, Leiden University Medic

Prosensa said the BIOIMAGE-NMD consortium received about €6 million ($8.1 million) from the EU's Seventh Framework Programme (FP7) to develop imaging biomarkers for rare neuromuscular diseases, including Duchenne muscular dystrophy (DMD). The project aims to...
07:00 , Aug 13, 2012 |  BC Week In Review  |  Clinical News

CardioSCORE regulatory update

BG Medicine withdrew a 510(k) application to FDA for its CardioSCORE diagnostic to identify patients at high risk for near-term major cardiovascular events, including heart attack or stroke. BG Medicine made the decision after determining...
00:23 , Aug 10, 2012 |  BC Extra  |  Company News

BG Medicine withdraws 510(k) for CardioSCORE

BG Medicine Inc. (NASDAQ:BGMD) withdrew a 510(k) application to FDA for its CardioSCORE (formerly AMIPredict ) diagnostic to identify patients at high risk for near-term major cardiovascular events, including heart attack or stroke. BG Medicine...
08:00 , Feb 20, 2012 |  BC Week In Review  |  Clinical News

CardioSCORE: Pivotal trial data

Data from the U.S. pivotal BioImage Study in 6,600 subjects with no prior history of cardiovascular disease showed that testing with BG Medicine's CardioSCORE diagnostic at baseline significantly improved the identification of subjects at high...
08:00 , Feb 20, 2012 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 2/17 cls BG Medicine Inc. (NASDAQ:BGMD) Ladenburg Thalmann Kevin DeGeeter Price target Buy -7% $7.90 DeGeeter raised his target to $16.50 from $8.25 after...
01:48 , Feb 14, 2012 |  BC Extra  |  Clinical News

BG Medicine reports data for CardioScore

BG Medicine Inc. (NASDAQ:BGMD) said that testing with its CardioScore diagnostic at baseline significantly improved the identification of subjects at high risk for near-term major cardiovascular events over conventional risk scoring throughout a median follow-up...
07:00 , Jul 13, 2009 |  BC Week In Review  |  Clinical News

BG Medicine, Humana Inc. pipeline update

BG and Humana completed enrollment of 6,822 volunteers in the observational BioImage study. Participants will provide blood samples and undergo a number of clinical tests, including advanced ultrasound examination of carotid arteries and a CT...
07:00 , Mar 30, 2009 |  BioCentury  |  Product Development

Triangulating heart markers

Now that BG Medicine Inc. has secured access to samples from the Framingham Heart Study, the company plans to set about validating a panel of markers it identified using samples from the Copenhagen Heart Study,...
08:00 , Jan 2, 2006 |  BC Week In Review  |  Company News

BioImage, TopoTarget deal

TOPO acquired from BioImage a preclinical cancer program that includes about 100 diphenyl ox-indole-2-one compounds, which act via the mTOR signaling pathway. TOPO plans to start Phase I testing of the lead candidate in 2007....